Skip to main
CAPR

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 14%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics is expected to have a positive future due to the potential approval of deramiocel for the treatment of DMD cardiomyopathy. The recent data presented at the MDA conference showed improvements in cardiac function, reduction of myocardial fibrosis, and slowing of disease progression. With the possibility of PRV and FDA approval, Capricor's market value is likely to increase significantly, making it a favorable investment option.

Bears say

Capricor Therapeutics is facing legal uncertainty with NS, which may increase stock volatility; however, the company's primary focus remains on preparing for Deramiocel's FDA approval and commercial launch. Despite the lawsuit with NS, Capricor has continued to advance Deramiocel through Phase 3 clinical development and has ramped up pre-launch efforts independently. There is potential for stock growth through the company's promising HOPE-3 data, but risks remain, including possible failed trials or funding challenges.

Capricor Therapeutics (CAPR) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 14% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Buy based on their latest research and market trends.

According to 7 analysts, Capricor Therapeutics (CAPR) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.